Cardiol Therapeutics (TSE:CRDL) Posts Quarterly Earnings Results

Cardiol Therapeutics (TSE:CRDL) announced its earnings results on Wednesday. The company reported C($0.05) EPS for the quarter, FiscalAI reports.

Cardiol Therapeutics Stock Up 0.5%

Shares of TSE:CRDL opened at C$2.12 on Thursday. The firm has a 50 day simple moving average of C$1.63 and a 200 day simple moving average of C$1.63. Cardiol Therapeutics has a 52 week low of C$1.23 and a 52 week high of C$2.33. The company has a debt-to-equity ratio of 0.48, a quick ratio of 6.84 and a current ratio of 4.39. The company has a market cap of C$244.38 million, a PE ratio of -5.44 and a beta of 0.27.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc ( NASDAQ: CRDL ) ( TSX: CRDL ) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx¿, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx¿ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations.